PL2945621T3 - Kompozycje farmaceutyczne zawierające donory nitroksylu - Google Patents

Kompozycje farmaceutyczne zawierające donory nitroksylu

Info

Publication number
PL2945621T3
PL2945621T3 PL14703010T PL14703010T PL2945621T3 PL 2945621 T3 PL2945621 T3 PL 2945621T3 PL 14703010 T PL14703010 T PL 14703010T PL 14703010 T PL14703010 T PL 14703010T PL 2945621 T3 PL2945621 T3 PL 2945621T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
nitroxyl donors
nitroxyl
donors
pharmaceutical
Prior art date
Application number
PL14703010T
Other languages
English (en)
Polish (pl)
Inventor
Vincent Jacob Kalish
John Reardon
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John P. Toscano
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of PL2945621T3 publication Critical patent/PL2945621T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14703010T 2013-01-18 2014-01-17 Kompozycje farmaceutyczne zawierające donory nitroksylu PL2945621T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
EP14703010.0A EP2945621B1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors
PCT/US2014/012089 WO2014113700A1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Publications (1)

Publication Number Publication Date
PL2945621T3 true PL2945621T3 (pl) 2019-05-31

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14703010T PL2945621T3 (pl) 2013-01-18 2014-01-17 Kompozycje farmaceutyczne zawierające donory nitroksylu
PL14703009T PL2945620T3 (pl) 2013-01-18 2014-01-17 Donory nitroksylu o korzystniejszym indeksie terapeutycznym
PL17195759T PL3284463T3 (pl) 2013-01-18 2014-01-17 Donory nitroksylu o korzystniejszym indeksie terapeutycznym

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL14703009T PL2945620T3 (pl) 2013-01-18 2014-01-17 Donory nitroksylu o korzystniejszym indeksie terapeutycznym
PL17195759T PL3284463T3 (pl) 2013-01-18 2014-01-17 Donory nitroksylu o korzystniejszym indeksie terapeutycznym

Country Status (29)

Country Link
US (13) US10245249B2 (enExample)
EP (5) EP3567031A1 (enExample)
JP (5) JP6449171B2 (enExample)
KR (2) KR102277165B1 (enExample)
CN (4) CN108610312A (enExample)
AU (5) AU2014207408C1 (enExample)
BR (2) BR112015017251B1 (enExample)
CA (2) CA2898443C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK2945620T3 (enExample)
ES (4) ES2751922T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20180121T1 (enExample)
HU (3) HUE046722T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT3284463T (enExample)
MX (2) MX363843B (enExample)
NZ (4) NZ709986A (enExample)
PL (3) PL2945621T3 (enExample)
PT (3) PT3284463T (enExample)
RS (3) RS56968B1 (enExample)
RU (3) RU2684916C2 (enExample)
SG (6) SG10201802855TA (enExample)
SI (3) SI3284463T1 (enExample)
SM (3) SMT201800088T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI712409B (enExample)
WO (2) WO2014113700A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811258T3 (es) 2006-03-17 2021-03-11 Univ Johns Hopkins Derivados de N-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiológicamente útiles
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
CN108368038A (zh) 2015-10-19 2018-08-03 卡尔迪奥克斯尔制药公司 作为硝酰基供体的n-羟基磺酰胺衍生物
JP7194436B2 (ja) 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
BR112019013702A2 (pt) 2017-01-03 2020-03-03 Cardioxyl Pharmaceuticals, Inc. Método de administração de compostos doadores de nitroxila
MX2019012535A (es) * 2017-04-18 2020-08-17 Genfit Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
KR970700646A (ko) * 1994-01-19 1997-02-12 헤르베르트 루프·울리히 볼프 니트록시기를 포함한 벤질아민 유도체, 및 심장 혈관 질환과 안압 상승의 치료를 위한 이의 용도(nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure)
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
AU741180B2 (en) 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
HUP0303857A3 (en) * 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
ES2811258T3 (es) 2006-03-17 2021-03-11 Univ Johns Hopkins Derivados de N-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiológicamente útiles
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
KR101905004B1 (ko) * 2007-09-26 2018-10-08 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
MX2010011924A (es) * 2008-05-07 2010-11-30 Cardioxyl Pharmaceuticals Inc Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
AU2010328234B2 (en) * 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
BR112014009282B1 (pt) 2011-10-17 2021-12-14 The Johns Hopkins University Composto, composição farmacêutica contendo-o e uso do mesmo
US9676708B2 (en) 2012-11-01 2017-06-13 The Johns Hopkins University Controlled HNO release through intramolecular cyclization-elimination
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
DK2945620T3 (en) 2018-02-05
AU2018203240B2 (en) 2019-12-12
AU2014207408B2 (en) 2018-03-01
US20220193026A1 (en) 2022-06-23
JP2019089764A (ja) 2019-06-13
RU2684916C2 (ru) 2019-04-16
AU2014207408C1 (en) 2018-09-06
IL239906B (en) 2018-05-31
US20240066002A1 (en) 2024-02-29
SG11201505567RA (en) 2015-09-29
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
HUE046722T2 (hu) 2020-03-30
PT3284463T (pt) 2019-10-30
NZ709986A (en) 2020-01-31
SG10201802855TA (en) 2018-05-30
US10517847B2 (en) 2019-12-31
CN105073105A (zh) 2015-11-18
JP6801045B2 (ja) 2020-12-16
IL239952A0 (en) 2015-08-31
BR112015017251A2 (pt) 2017-07-11
AU2017200147B2 (en) 2018-07-05
HRP20182144T1 (hr) 2019-03-08
HK1216857A1 (en) 2016-12-09
KR20150107853A (ko) 2015-09-23
TW201442702A (zh) 2014-11-16
HRP20191919T1 (hr) 2020-01-10
DK3284463T3 (da) 2019-10-28
CA2898443A1 (en) 2014-07-24
RU2018143994A (ru) 2019-01-16
CN110179777B (zh) 2022-07-15
KR102277165B1 (ko) 2021-07-14
KR102177899B1 (ko) 2020-11-12
CN110179777A (zh) 2019-08-30
US10548872B2 (en) 2020-02-04
AU2018203240A1 (en) 2018-05-31
SG10201913286PA (en) 2020-02-27
LT3284463T (lt) 2019-11-11
US20180235927A1 (en) 2018-08-23
CN105142627A (zh) 2015-12-09
PL3284463T3 (pl) 2019-12-31
CN105142627B (zh) 2019-06-21
SI3284463T1 (sl) 2019-12-31
SMT201800088T1 (it) 2018-03-08
IL258882A (en) 2018-06-28
CN108610312A (zh) 2018-10-02
TWI686193B (zh) 2020-03-01
NZ709985A (en) 2020-05-29
CA2898445C (en) 2022-05-03
SG10201802862WA (en) 2018-05-30
TWI619491B (zh) 2018-04-01
US12186301B2 (en) 2025-01-07
SI2945620T1 (en) 2018-01-31
NZ748771A (en) 2019-12-20
TWI712409B (zh) 2020-12-11
JP6533159B2 (ja) 2019-06-19
EP3427728B1 (en) 2021-07-07
CY1122177T1 (el) 2020-11-25
US20210015784A1 (en) 2021-01-21
HRP20180121T1 (hr) 2018-02-23
US20190133990A1 (en) 2019-05-09
IL259233B (en) 2019-10-31
HK1216858A1 (en) 2016-12-09
TR201802211T4 (tr) 2018-03-21
EP2945620A1 (en) 2015-11-25
SG10201913441RA (en) 2020-03-30
WO2014113696A1 (en) 2014-07-24
BR112015017241B1 (pt) 2021-10-26
MX373176B (es) 2020-04-22
HUE041861T2 (hu) 2019-06-28
CA2898443C (en) 2022-05-31
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
ES2705240T3 (es) 2019-03-22
EP2945620B1 (en) 2017-11-22
JP2019172682A (ja) 2019-10-10
US20190224159A1 (en) 2019-07-25
KR20150108879A (ko) 2015-09-30
US10792273B2 (en) 2020-10-06
BR112015017241A8 (pt) 2019-10-29
EP3284463B1 (en) 2019-07-24
SMT201900027T1 (it) 2019-02-28
JP2017125015A (ja) 2017-07-20
AU2018241168A1 (en) 2018-11-01
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
RS59434B1 (sr) 2019-11-29
JP2016505044A (ja) 2016-02-18
BR112015017251A8 (pt) 2019-10-29
TW201446242A (zh) 2014-12-16
AU2014207408A8 (en) 2015-08-27
US11273143B2 (en) 2022-03-15
US10245249B2 (en) 2019-04-02
LT2945621T (lt) 2019-01-10
RS58174B1 (sr) 2019-03-29
AU2018241168B2 (en) 2020-04-02
EP3567031A1 (en) 2019-11-13
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
ES2882279T3 (es) 2021-12-01
DK2945621T3 (en) 2019-02-11
EP3427728A1 (en) 2019-01-16
ES2751922T3 (es) 2020-04-02
MX2015009276A (es) 2015-10-30
HUE036589T2 (hu) 2018-07-30
CA2898445A1 (en) 2014-07-24
US20200163929A1 (en) 2020-05-28
US20170151210A1 (en) 2017-06-01
US9968584B2 (en) 2018-05-15
ES2659969T3 (es) 2018-03-20
IL259233A (en) 2018-07-31
US9156804B2 (en) 2015-10-13
WO2014113700A1 (en) 2014-07-24
JP2016510326A (ja) 2016-04-07
JP6656345B2 (ja) 2020-03-04
MX363843B (es) 2019-04-05
SI2945621T1 (sl) 2019-01-31
AU2014207404A1 (en) 2015-08-13
RU2676277C2 (ru) 2018-12-27
PT2945621T (pt) 2019-01-21
NZ748769A (en) 2020-05-29
AU2014207408A1 (en) 2015-08-13
BR112015017241A2 (pt) 2017-07-11
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
WO2014113700A9 (en) 2014-10-09
US8987326B2 (en) 2015-03-24
JP6449171B2 (ja) 2019-01-09
PT2945620T (pt) 2018-02-21
SMT201900575T1 (it) 2019-11-13
US10213408B2 (en) 2019-02-26
JP6311038B2 (ja) 2018-04-11
BR112015017251B1 (pt) 2021-10-26
TW201934120A (zh) 2019-09-01
US20150175566A1 (en) 2015-06-25
MX2015009269A (es) 2015-10-30
US11786501B2 (en) 2023-10-17
PL2945620T3 (pl) 2018-03-30
ZA201505090B (en) 2016-10-26
LT2945620T (lt) 2018-02-12
CY1121480T1 (el) 2020-05-29
CN105073105B (zh) 2018-02-27
EP3284463A1 (en) 2018-02-21
HRP20191919T8 (hr) 2021-10-01
HK1251170B (en) 2020-04-09
AU2014207404B2 (en) 2017-10-19
US20140206769A1 (en) 2014-07-24
RU2015134583A (ru) 2017-02-22
IL239906A0 (en) 2015-08-31
IL239952B (en) 2018-05-31
ZA201604798B (en) 2018-01-31
US9586896B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
IL259233A (en) Pharmaceutical preparations containing nitroxyl donors
PL2943181T3 (pl) Kompozycje farmaceutyczne
SMT201900684T1 (it) Composizione farmaceutica combinata
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
GB201306610D0 (en) Pharmaceutical compounds
ZA201408333B (en) Pharmaceutical compositions
IL241254A0 (en) Pharmaceutical preparations containing everolimus
EP3003324A4 (en) Pharmaceutical compositions
SG11201601477VA (en) Pharmaceutical composition
ZA201506637B (en) Micronized pharmaceutical compositions
GB201312386D0 (en) Pharmaceutical compounds
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
IL244365A0 (en) pharmaceutical preparation
SG11201509114TA (en) Pharmaceutical compositions
GB201304699D0 (en) Pharmaceutical compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
GB201308780D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308782D0 (en) Pharmaceutical compounds